Did Medtronic’s (MDT) Positive Renal Denervation Results Just Shift Its Hypertension Device Narrative?

• In late October 2025, Medtronic announced new three-year clinical results at the TCT conference showing its Symplicity Spyral renal denervation system significantly reduced blood pressure without major safety issues compared to the control group.
• The reported absence of serious long-term side effects, such as renal artery stenosis, strengthens the commercial and regulatory outlook for this hypertension device in nearly 80 global markets.
• We’ll examine how these long-term clinical outcomes could influence Medtronic’s investment narrative focused on hypertension solutions and pipeline innovation.

Find companies with promising cash flow potential yet trading below their fair value.

Medtronic Investment Narrative Recap

For many investors, the investment thesis for Medtronic centers on robust demand for advanced devices tackling chronic disease, a strong innovation pipeline, and the company’s ability to turn R&D into sustained earnings growth. The newly released three-year data for Symplicity Spyral is a clear catalyst for the hypertension franchise, but it does not materially alter the most immediate risk: continued margin pressure from product mix and growth challenges in core segments like Diabetes and MedSurg. The short-term focus remains on whether Medtronic can stabilize margins as new products reach commercial scale.

Among recent announcements, the Q1 2026 earnings report highlighted stable revenue at US$8,578 million and net income of US$1,040 million, reflecting the company’s steady base amid pockets of innovation. This performance anchors Medtronic’s financial resilience, even as attention shifts to whether clinical milestones like the SPYRAL trial can drive outsized gains across more challenged product areas. Yet, while the innovation pipeline appears promising, investors should keep a close eye on...

Read the full narrative on Medtronic (it's free!)

Medtronic is projected to reach $40.0 billion in revenue and $6.3 billion in earnings by 2028. This outlook assumes 5.4% annual revenue growth and a $1.6 billion increase in earnings from the current $4.7 billion.

Uncover how Medtronic's forecasts yield a $101.13 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community fair value estimates for Medtronic span from US$82.66 to US$101.13 based on seven independent submissions. As you weigh these opinions, remember recent clinical wins could influence future growth, but ongoing margin pressures remain a key point of focus for all market participants.

Explore 7 other fair value estimates on Medtronic - why the stock might be worth as much as 10% more than the current price!

Build Your Own Medtronic Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Medtronic research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Rare earth metals are the new gold rush. Find out which 35 stocks are leading the charge.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com